Sanofi-Aventis becomes Genzyme's suitor

NEW YORK French drug maker Sanofi-Aventis has made an offer for Genzyme, according to published reports.

The Wall Street Journal reported Monday that Sanofi was in “friendly” acquisition talks with Cambridge, Mass.-based Genzyme and had offered to buy the biotech company for around $70 per share.

Rumors already had begun circulating that Sanofi would buy Genzyme, which specializes in making drugs for treating rare genetic disorders.

Recommended stories

Login or Register to post a comment.